On November 24, 2020 SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, reported the Company’s participation in Piper Sandler’s 32nd Annual Virtual Healthcare Conference (Press release, Scynexis, NOV 24, 2020, View Source [SID1234571673]). Presentations will be available for registered attendees via the Piper Sandler conference site from November 23 to December 3, 2020. The Company will also participate in a panel discussion at Evercore ISI’s 3rd Annual HealthCONx Conference taking place on December 2, 2020.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation details:

Piper Sandler 32nd Annual Virtual Healthcare Conference:
Presentation Date: Monday, November 23 to Thursday, December 3, 2020
Presentation Time: 8:00 a.m. – 5:00 p.m. ET
Webcast:
Link

Evercore ISI 3rd Annual HealthCONx Conference:
Panel Discussion Topic:
No Fungus Among Us: Addressing an Important Need with Cidara, F2G, and SCYNEXIS
Presentation Date: Wednesday, December 2, 2020
Presentation Time: 11:20 a.m. – 12:05 p.m. ET

A webcast of both presentation recordings will be available for 30 days and can be found on the Scynexis website at: View Source

On November 24, 2020 Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, reported management’s participation in the following investor conferences in December (Press release, Immunic, NOV 24, 2020, View Source [SID1234571695]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

November 30 – December 3: Piper Sandler 32nd Virtual Healthcare Conference. Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, will participate in a fireside chat. Beginning November 23, the fireside chat will be available for viewing anytime through December 3 by accessing the recording library on the Piper Sandler conference site. An archived replay of the presentation will be available on the "Events and Presentations" section of Immunic’s website at: ir.imux.com/events-and-presentations for a period of 90 days after the conference.
December 1-3: Evercore ISI 3rd Annual HEALTHCONx Conference. Dr. Vitt will participate in a fireside chat on Thursday, December 3, at 12:10 pm ET. A live audio webcast of the presentation will be available on the "Events and Presentations" section of Immunic’s website at: ir.imux.com/events-and-presentations. An archived replay will be available on the company’s website for a period of one year after the conference.

On November 24, 2020 the Spanish start-up, specialized in developing a technology to transport drugs to the brain, reported the company is seeking up to three million euros to reach the clinical trial (Press release, Gate2Brain, NOV 24, 2020, View Source [SID1234641077]). The CEO of Gate2Brain, Meritxell Teixidó, explains to PlantaDoce that the company plans to open a financing round in April 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The start-up develops a technology to transport drugs to the brain . The company will use the funds to advance therapeutic tests since, although it has identified the drug to deliver to this organ according to the group of pediatric brain tumors, it must improve transport.

In this way, the company would increase the effectiveness of brain disease treatments with its technology, while reducing side effects. Teixidó assures that the objective is "to validate the platform and for a pharmaceutical company to look at it to acquire the company . "

Gate2Brain seeks to improve the effectiveness of brain disease treatments

The company is a spin off of the Barcelona Biomedical Research Institute, the University of Barcelona (UB) and the Sant Joan de Déu Research Institute of the Sant Joan de Déu Hospital (SJD). The company has its headquarters in the Barcelona Science Park.

Gate2Brain envisions its technology will allow drugmakers to recover promising drugs that don’t make it to market because they can’t be transported to the brain. The company’s CEO states that "98% of drug candidates are discarded because they do not pass the barrier and our technology would allow investment in these drugs not to be left in a corner." The company is in contact with some pharmaceutical companies .

The start-up plans to open a financing round of between two million euros and three million euros in April 2021 . Gate2Brain estimates to begin the clinical trial in 2023. The company has carried out some tests at the Sant Joan de Déu Hospital in Barcelona and has observed that its technology would have applicability in various tumors.

Gate2Brain has received funding from the Botín Foundation

Gate2Brain has received support from the Botín Foundation’s Mind The Gap Program, which invests up to half a million euros per project . The start-up obtained online research support from the CaixaImpulse program of the La Caixa Foundation and funding from the Agency for Management and University Research Grants (Agaur) in the Knowledge Industry Grants call.

The company currently has five workers. Gate2Brain, founded by Teixidó and three other entrepreneurs, has Marc Ramis, CEO of Ninevah Therapeutics, as an advisor. The founders control the majority of the company’s shareholders.

On November 24, 2020 Advaxis, Inc. (Nasdaq: ADXS) (the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, reported the pricing of an underwritten public offering of (i) 26,666,666 shares of common stock and warrants to purchase up to 13,333,333 shares of common stock (Press release, Advaxis, NOV 24, 2020, View Source [SID1234571652]). The shares of common stock and warrants are being sold together at a combined public offering price of $0.30 per share. The warrants will have an exercise price of $0.35 per share, will be immediately exercisable and will expire five years from the date of issuance. The Company has granted the underwriters a 30-day option to purchase up to an additional 3,999,999 shares of common stock and/or 1,999,999 warrants to cover over-allotments, if any.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company plans to use the net proceeds from the offering to fund its continued research and development initiatives in connection with expanding its product pipeline including, but not limited to, investment in its ADXS-HOT program and for general corporate purposes. The Company may also use a portion of the net proceeds to acquire or invest in other businesses, products and technologies.

A.G.P./Alliance Global Partners is acting as sole book-running manager for the offering.

This offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-226988) previously filed with the U.S. Securities and Exchange Commission (the "SEC"), and an additional registration statement on Form S-3 filed pursuant to Rule 462(b) under the Securities Act, which became effective upon filing on August 30, 2018. A prospectus supplement describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov. Electronic copies of the prospectus supplement may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022 or via telephone at 212-624-2060 or email: [email protected]. Before investing in this offering, interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering. Copies of the Supplement, the Base Shelf Prospectus and the Registration Statement may also be obtained from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022 or via telephone at 212-624-2060 or email: [email protected].

No securities regulatory authority has either approved or disapproved of the contents of this press release. This press release is for information purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

On November 24, 2020 Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company") a company focused on the creation of the Terra CoV-2 vaccine candidate to combat the novel coronavirus pandemic, reported, the closing of its previously announced underwritten public offering of 14,189,189 shares of common stock at a price to the public of $0.37 per share (Press release, Oragenics, NOV 24, 2020, View Source [SID1234571675]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oragenics expects to receive gross proceeds of approximately $6.0 million from the offering.

A.G.P./Alliance Global Partners is acting as sole book-running manager for the offering.

The Company granted the underwriter a 45-day option to purchase up to 2,128,378 additional shares of common stock at the public offering price, less underwriting discounts and commissions. The underwriter exercised its option in full to purchase 2,128,378 additional shares of common stock, which the indicated gross proceeds reflect.

The Company intends to use the net proceeds of the offering primarily to continue funding our pre-clinical development of our SARS-CoV-2 vaccine, Terra CoV-2 and our lantibiotics program and for general corporate purposes, including research and development activities, capital expenditures and working capital.

This offering is being made pursuant to an effective shelf registration statement on Form S-3 (No. 333-235763) previously filed with the U.S. Securities and Exchange Commission (the "SEC") that was declared effective by the SEC on January 13, 2020. A prospectus supplement and accompanying prospectus describing the terms of the proposed offering was filed with the SEC and is available on the SEC’s website at www.sec.gov. Electronic copies of the prospectus supplement may be obtained from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022 or via telephone at 212-624-2060 or email: [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the Company’s securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.